These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 2569697)

  • 1. Physiology and pharmacology of dopamine D2-receptors: their implications in dopamine-substitute therapy for Parkinson's disease.
    Mercuri NB; Calabresi P; Bernardi G
    Neurology; 1989 Aug; 39(8):1106-8. PubMed ID: 2569697
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanism of action of dopaminergic agents in Parkinson's disease.
    Koller WC; Rueda MG
    Neurology; 1998 Jun; 50(6 Suppl 6):S11-4; discussion S44-8. PubMed ID: 9633680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences.
    Thobois S; Jahanshahi M; Pinto S; Frackowiak R; Limousin-Dowsey P
    Neuroimage; 2004 Sep; 23(1):1-16. PubMed ID: 15325346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what.
    Metman LV; Konitsiotis S; Chase TN
    Mov Disord; 2000 Jan; 15(1):3-8. PubMed ID: 10634235
    [No Abstract]   [Full Text] [Related]  

  • 5. Three types of akinesia in the progressive course of Parkinson's disease.
    Narabayashi H
    Adv Neurol; 1993; 60():18-24. PubMed ID: 8093577
    [No Abstract]   [Full Text] [Related]  

  • 6. Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
    Melamed E
    Adv Neurol; 1990; 53():61-6. PubMed ID: 2173376
    [No Abstract]   [Full Text] [Related]  

  • 7. Pathogenesis and animal studies of Parkinson's disease.
    Oertel WH; Kupsch A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms.
    Hornykiewicz O
    Adv Neurol; 1993; 60():140-7. PubMed ID: 8420131
    [No Abstract]   [Full Text] [Related]  

  • 9. Partial damage to nigrostriatal bundle: compensatory changes and the action of L-dopa.
    Zigmond MJ; Abercrombie ED; Stricker EM
    J Neural Transm Suppl; 1990; 29():217-32. PubMed ID: 2193107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dopamine agonists in the therapy of parkinson syndrome].
    Kapfhammer HP; Rüther E
    Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
    [No Abstract]   [Full Text] [Related]  

  • 11. Synergistic interactions of D1- and D2-selective dopamine agonists in animal models for Parkinson's disease: sites of action and implications for the pathogenesis of dyskinesias.
    Robertson HA
    Can J Neurol Sci; 1992 Feb; 19(1 Suppl):147-52. PubMed ID: 1349263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular neuroanatomic mechanisms of Parkinson's disease: a proposed therapeutic approach.
    Gerfen CR; Engber TM
    Neurol Clin; 1992 May; 10(2):435-49. PubMed ID: 1350051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotection by anti-oxidant strategies in Parkinson's disease.
    LeWitt PA
    Eur Neurol; 1993; 33 Suppl 1():24-30. PubMed ID: 8375428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Ottorino Rossi" Award 2000. New targets for therapy in Parkinson's disease: pathogenesis and pathophysiology.
    Greenamyre JT
    Funct Neurol; 2000; 15(2):67-80. PubMed ID: 10916718
    [No Abstract]   [Full Text] [Related]  

  • 15. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
    Calabresi P; Mercuri NB; Sancesario G; Bernardi G
    Brain; 1993 Apr; 116 ( Pt 2)():433-52. PubMed ID: 8096420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medications for Parkinson's disease.
    Whitney CM
    Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
    [No Abstract]   [Full Text] [Related]  

  • 17. Free radicals and their scavengers in Parkinson's disease.
    Yoshikawa T
    Eur Neurol; 1993; 33 Suppl 1():60-8. PubMed ID: 8375435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy of Parkinson's disease: research from 1960 to 1991.
    Pletscher A; DaPrada M
    Acta Neurol Scand Suppl; 1993; 146():26-31. PubMed ID: 8101413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features, diagnosis, and imaging of parkinsonian syndromes.
    Poewe W
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):333-8. PubMed ID: 8507902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical aspects of Parkinson's disease.
    Nagatsu T
    Adv Neurol; 1993; 60():165-74. PubMed ID: 8093575
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.